Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122944 | 0.84 | SHMT2 (0.62) | HTTSHMT2KDM4EGAATSHR | |
| SCHEMBL5128181 | 0.82 | MAP4K4 (0.43) | P2RX7MAP4K4KDM4EGAA | |
| SCHEMBL4918026 | 0.81 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL4779101 | 0.78 | NPC1 (0.51) | HTTKDM4EGAATSHRCASP1 | |
| SCHEMBL31381338 | 0.78 | LMNA (0.59) | LMNAHTTNOTUMKDM4EHSD17B10 | |
| SCHEMBL24844621 | 0.77 | HRH3 (0.62) | LMNAHTTNOTUMKDM4EHSD17B10 | |
| SCHEMBL1805833 | 0.75 | P2RX7 (0.58) | LMNAHTTP2RX7MAP4K4 | |
| SCHEMBL27162504 | 0.75 | LMNA (0.47) | LMNAHTTNOTUM | |
| SCHEMBL1804368 | 0.74 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL1813063 | 0.74 | P2RX7 (0.51) | LMNAHTTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1832925-B | New P2X7 receptor avtagonists and their use | ASTRAZENECA AB | 2010-05-05 | — | — | CN | disclosed |
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| CN-1832925-A | New p2x7 receptor avtagonists and their use | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | disclosed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | LMNA 1654/4885HTT 3159/4885P2RX7 1/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | LMNA 1654/4885HTT 3159/4885P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.